News

Rituximab treatment resolves serious case of secondary CAD

Treatment with rituximab — commonly used off-label for cold agglutinin disease (CAD) — was reported to successfully resolve a serious case of CAD secondary to an Epstein-Barr virus (EBV) infection and potential contraceptive pill toxicity in a young woman in Europe. The woman had developed severe jaundice and liver…

Review study highlights challenges in CAD treatment, diagnosis

Establishing a diagnosis of autoimmune hemolytic anemia (AIHA), a group of conditions including cold agglutinin disease (CAD), is sometimes difficult, due to the high variability in signs and symptoms and the possibility of a secondary cause, a review study showed. “Additionally, therapy is poorly evidence-based and mainly funded on…

AI model helps identify medications to repurpose for rare diseases

Researchers have developed an artificial intelligence (AI)-based model designed to identify existing medicines that could be repurposed to treat rare conditions such as cold agglutinin disease (CAD). The model, called TxGNN, was able to identify possible therapeutic candidates for more than 17,000 conditions in a study, and researchers believe…

How to define and treat childhood AIHA can vary widely: Review

How childhood autoimmune hemolytic anemia (AIHA) — a group of rare conditions that includes cold agglutinin disease (CAD) — is defined and classified varies widely, as does the approach to care for children with hard-to-treat disease, a review study shows. “Standardized definitions and classifications are needed to guide collaborative efforts…

In girl, secondary cold agglutinin disease seen to mimic vasculitis

In a young girl in India, cold agglutinin disease (CAD) secondary to a respiratory infection resulted in symptoms suggestive of vasculitis, a group of conditions marked by blood vessel inflammation, a study reported. The symptoms mimicking vasculitis included blueish-blackish discoloration of the nose’s tip that indicated tissue cell death…